Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel an...
What potential catalysts or headwinds should traders monitor that could drive the stock price in the short to medium term?
Are there any changes in the company's capital structure, such as share issuances or stock option grants, that could dilute existing shareholders?
What is the market's perception of the risk/reward profile for investing in Jasper Therapeutics based on this earnings release?
11 days ago